This blog exists to extend and apply the intellectual framework introduced by Yung-Chi Cheng and colleagues at Yale School of Medicine — the idea that the future of medicine lies not in choosing between Western pharmacology and Eastern botanical tradition, but in rigorously merging them.
Current drug development still largely applies a reductionist approach: identify one target, synthesize one potent molecule, run one clinical trial. This has produced remarkable medicines — and a growing list of failures for complex, heterogeneous, aging-associated diseases where the biology doesn't cooperate with the model.
Traditional Chinese Medicine has, for thousands of years, operated on a different premise: that health conditions arise from systemic imbalances requiring multicompound, multi-target interventions. Its mechanisms were opaque to modern science. They no longer have to be.
Systems biology, network pharmacology, omics technologies, and mechanism-based quality control methods now give us the tools to study what botanical formulas actually do — at the molecular, cellular, tissue, and whole-body level. This is the work this blog tracks and supports.
Cheng's framework is elegantly simple: Western (W) medicine excels at microscopic, single-target precision. Eastern (E) medicine excels at macroscopic, systems-level holism. Neither is sufficient for the full spectrum of human health needs. The convergence — WE Medicine — is not a compromise. It is an upgrade.
This blog explores that convergence through pharmacology, research methodology, case studies, and critical analysis of where the field is heading.
Essays on the paradigm itself. Deep dives into network pharmacology and systems biology. Case studies of botanical drugs being validated through rigorous modern science. Critical analysis of research methodology. Profiles of researchers working at the convergence. And honest engagement with the challenges — regulatory, scientific, and cultural — that the field still faces.
The standard here is evidence. The orientation is integrative. The goal is clarity.
This blog draws centrally on the work of Yung-Chi Cheng (Department of Pharmacology, Yale School of Medicine), particularly his 2019 paper The Evolution of Future Medicine — WE Medicine — To Meet Unmet Medical Needs, published in Novel Approaches in Cancer Study. The WE Medicine framework is his. This blog applies and extends it.